GENMAB A/S -SP ADR (GMAB) Fundamental Analysis & Valuation

NASDAQ:GMAB • US3723032062

Current stock price

27.06 USD
-0.85 (-3.05%)
At close:
28 USD
+0.94 (+3.47%)
Pre-Market:

This GMAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. GMAB Profitability Analysis

1.1 Basic Checks

  • In the past year GMAB was profitable.
  • In the past year GMAB had a positive cash flow from operations.
  • In the past 5 years GMAB has always been profitable.
  • Each year in the past 5 years GMAB had a positive operating cash flow.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • GMAB has a better Return On Assets (7.48%) than 92.44% of its industry peers.
  • With an excellent Return On Equity value of 16.47%, GMAB belongs to the best of the industry, outperforming 93.99% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 9.04%, GMAB belongs to the best of the industry, outperforming 92.64% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for GMAB is significantly below the industry average of 27.75%.
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROIC 9.04%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • GMAB has a better Profit Margin (25.89%) than 93.60% of its industry peers.
  • GMAB's Profit Margin has declined in the last couple of years.
  • GMAB's Operating Margin of 33.60% is amongst the best of the industry. GMAB outperforms 96.12% of its industry peers.
  • GMAB's Operating Margin has declined in the last couple of years.
  • GMAB has a better Gross Margin (93.60%) than 94.57% of its industry peers.
  • In the last couple of years the Gross Margin of GMAB has declined.
Industry RankSector Rank
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GMAB Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
  • The number of shares outstanding for GMAB has been reduced compared to 1 year ago.
  • Compared to 5 years ago, GMAB has less shares outstanding
  • The debt/assets ratio for GMAB is higher compared to a year ago.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 2.61 indicates that GMAB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GMAB has a Altman-Z score of 2.61. This is in the better half of the industry: GMAB outperforms 66.47% of its industry peers.
  • GMAB has a debt to FCF ratio of 4.80. This is a neutral value as GMAB would need 4.80 years to pay back of all of its debts.
  • GMAB has a Debt to FCF ratio of 4.80. This is amongst the best in the industry. GMAB outperforms 91.67% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.88. This is a neutral value indicating GMAB is somewhat dependend on debt financing.
  • GMAB has a Debt to Equity ratio of 0.88. This is in the lower half of the industry: GMAB underperforms 74.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Altman-Z 2.61
ROIC/WACC1.44
WACC6.27%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 2.02 indicates that GMAB has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.02, GMAB is doing worse than 77.33% of the companies in the same industry.
  • A Quick Ratio of 2.01 indicates that GMAB has no problem at all paying its short term obligations.
  • GMAB's Quick ratio of 2.01 is on the low side compared to the rest of the industry. GMAB is outperformed by 75.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GMAB Growth Analysis

3.1 Past

  • The earnings per share for GMAB have decreased by -2.61% in the last year.
  • The Earnings Per Share has been growing by 9.47% on average over the past years. This is quite good.
  • GMAB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.25%.
  • The Revenue has been growing by 19.19% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%

3.2 Future

  • Based on estimates for the next years, GMAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.88% on average per year.
  • The Revenue is expected to grow by 12.86% on average over the next years. This is quite good.
EPS Next Y-27.83%
EPS Next 2Y0.46%
EPS Next 3Y15.01%
EPS Next 5Y9.88%
Revenue Next Year18.39%
Revenue Next 2Y17.21%
Revenue Next 3Y16.79%
Revenue Next 5Y12.86%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. GMAB Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.46, the valuation of GMAB can be described as correct.
  • Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 95.54% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.71. GMAB is valued slightly cheaper when compared to this.
  • The Price/Forward Earnings ratio is 21.38, which indicates a rather expensive current valuation of GMAB.
  • 94.19% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
  • GMAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 38.09.
Industry RankSector Rank
PE 15.46
Fwd PE 21.38
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 93.80% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, GMAB is valued cheaper than 96.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.69
EV/EBITDA 15.38
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • GMAB has a very decent profitability rating, which may justify a higher PE ratio.
  • GMAB's earnings are expected to grow with 15.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)1.63
EPS Next 2Y0.46%
EPS Next 3Y15.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GMAB Dividend Analysis

5.1 Amount

  • GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GMAB Fundamentals: All Metrics, Ratios and Statistics

GENMAB A/S -SP ADR

NASDAQ:GMAB (4/21/2026, 8:00:01 PM)

Premarket: 28 +0.94 (+3.47%)

27.06

-0.85 (-3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners43.37%
Inst Owner Change-0.19%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.61B
Revenue(TTM)3.72B
Net Income(TTM)963.00M
Analysts74.07
Price Target34.46 (27.35%)
Short Float %1.46%
Short Ratio5.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.37%
Min EPS beat(2)-39.11%
Max EPS beat(2)36.36%
EPS beat(4)3
Avg EPS beat(4)18.01%
Min EPS beat(4)-39.11%
Max EPS beat(4)49.64%
EPS beat(8)6
Avg EPS beat(8)33.48%
EPS beat(12)8
Avg EPS beat(12)19.29%
EPS beat(16)11
Avg EPS beat(16)25.94%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.19%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.09%
Revenue beat(8)6
Avg Revenue beat(8)225.98%
Revenue beat(12)10
Avg Revenue beat(12)350.6%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)-74.6%
PT rev (3m)-74.6%
EPS NQ rev (1m)-27.81%
EPS NQ rev (3m)-65.08%
EPS NY rev (1m)-14.77%
EPS NY rev (3m)-28.21%
Revenue NQ rev (1m)0.71%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.85%
Valuation
Industry RankSector Rank
PE 15.46
Fwd PE 21.38
P/S 4.47
P/FCF 14.69
P/OCF 14.01
P/B 2.84
P/tB N/A
EV/EBITDA 15.38
EPS(TTM)1.75
EY6.47%
EPS(NY)1.27
Fwd EY4.68%
FCF(TTM)1.84
FCFY6.81%
OCF(TTM)1.93
OCFY7.14%
SpS6.06
BVpS9.52
TBVpS-5.91
PEG (NY)N/A
PEG (5Y)1.63
Graham Number19.3653 (-28.44%)
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROCE 10.92%
ROIC 9.04%
ROICexc 10.63%
ROICexgc 409.04%
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
FCFM 30.4%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
ROICexc(3y)44.94%
ROICexc(5y)57.79%
ROICexgc(3y)214.92%
ROICexgc(5y)161.21%
ROCE(3y)15.08%
ROCE(5y)16.09%
ROICexgc growth 3Y67.71%
ROICexgc growth 5Y24.23%
ROICexc growth 3Y-49.91%
ROICexc growth 5Y-39%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Debt/EBITDA 3.89
Cap/Depr 77.46%
Cap/Sales 1.48%
Interest Coverage 125
Cash Conversion 89.78%
Profit Quality 117.45%
Current Ratio 2.02
Quick Ratio 2.01
Altman-Z 2.61
F-Score4
WACC6.27%
ROIC/WACC1.44
Cap/Depr(3y)92.84%
Cap/Depr(5y)93.54%
Cap/Sales(3y)1.72%
Cap/Sales(5y)2.07%
Profit Quality(3y)124.53%
Profit Quality(5y)101.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
EPS Next Y-27.83%
EPS Next 2Y0.46%
EPS Next 3Y15.01%
EPS Next 5Y9.88%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%
Revenue Next Year18.39%
Revenue Next 2Y17.21%
Revenue Next 3Y16.79%
Revenue Next 5Y12.86%
EBIT growth 1Y24.57%
EBIT growth 3Y12.48%
EBIT growth 5Y5.6%
EBIT Next Year-3.74%
EBIT Next 3Y18.03%
EBIT Next 5Y4.81%
FCF growth 1Y4.43%
FCF growth 3Y30.57%
FCF growth 5Y3.84%
OCF growth 1Y5.23%
OCF growth 3Y28.97%
OCF growth 5Y3.81%

GENMAB A/S -SP ADR / GMAB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 6 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


What is the profitability of GMAB stock?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


What is the earnings growth outlook for GENMAB A/S -SP ADR?

The Earnings per Share (EPS) of GENMAB A/S -SP ADR (GMAB) is expected to decline by -27.83% in the next year.